Salarius Pharmaceuticals EBITDA 2015-2024 | SLRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Salarius Pharmaceuticals ebitda from 2015 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Salarius Pharmaceuticals ebitda from 2015 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$80.4B
Zoetis (ZTS)	$70.5B
Takeda Pharmaceutical (TAK)	$44.1B
Daiichi Sankyo, - (DSNKY)	$43.3B
Sandoz Group AG (SDZNY)	$20.6B
Merck (MKKGY)	$18.5B
Astellas Pharma (ALPMY)	$17.5B
Summit Therapeutics (SMMT)	$17B
United Therapeutics (UTHR)	$16.4B
Shionogi (SGIOY)	$12.3B
Neurocrine Biosciences (NBIX)	$11.6B
Orion OYJ (ORINY)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.7B
Corcept Therapeutics (CORT)	$6.8B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Stevanato Group S.p.A (STVN)	$6.2B
Ionis Pharmaceuticals (IONS)	$5.2B
Grifols, S.A (GRFS)	$5.2B
Ono Pharmaceutical (OPHLF)	$4.7B
Recursion Pharmaceuticals (RXRX)	$4B
Crinetics Pharmaceuticals (CRNX)	$3.4B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.2B
Hypermarcas (HYPMY)	$2.2B
Soleno Therapeutics (SLNO)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.8B
Evotec AG (EVO)	$1.6B
Dyne Therapeutics (DYN)	$1.4B